Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 1

Daylight Photodynamic Therapy for Actinic Keratosis

NCT03322293 · View on ClinicalTrials.gov ↗

Study Summary

This is a randomized, single-blind controlled trial with parallel group design to determine whether daylight photodynamic therapy (PDT) affords a reduction in treatment symptoms of pain, burning, and pruritus as measured by 1) symptom level during the treatment period and 2) pain at the end of treatment exposure.

Conditions Studied

Interventions

  • DRUG Aminolevulinic Acid Topical 20% Topical Solution
  • DEVICE BLU-U blue light phototherapy illuminator

Study Locations (1)

California

  • UCSF Dermatology — San Francisco

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2017-12-01
Est. Completion 2019-07-01
Phase Phase 1

Sponsor

University of California, San Francis

1,574 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03322293

The ClinicalTrials.gov registry entry for NCT03322293 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francis, which has 1,574 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Actinic Keratoses appearing as the primary indexed condition, and to 2 interventions — of which Aminolevulinic Acid Topical 20% Topical Solution is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03322293 reports 1 study location spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03322293 about?

NCT03322293 is a clinical study titled "Daylight Photodynamic Therapy for Actinic Keratosis". This is a randomized, single-blind controlled trial with parallel group design to determine whether daylight photodynamic therapy (PDT) affords a reduction in treatment symptoms of pain, burning, and pruritus as measured by 1) symptom level during the treatment period and 2) pain at the end of treat...

What is the current status of trial NCT03322293?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-12-01. Estimated completion is 2019-07-01.

What conditions does trial NCT03322293 study?

This clinical trial studies the following conditions: Actinic Keratoses. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03322293?

The interventions under investigation include: Aminolevulinic Acid Topical 20% Topical Solution (DRUG), BLU-U blue light phototherapy illuminator (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03322293?

This trial is sponsored by University of California, San Francis, which has 1,574 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03322293 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial